Delcath Systems, Inc. (NASDAQ: DCTH) announced that Dr. Charles Nutting, a principal investigator in one of the company’s drug trials, will present at the Western Angiographic and Interventional Society Annual Meeting.
During the Sept. 20-25 conference, Dr. Nutting of the Swedish Medical Center in Englewood, Colo. will discuss his involvement with the Phase 3 trial of Delcath’s Percutaneous Hepatic Perfusion (PHP) System.
“This is the first major presentation regarding the Phase III trial by an Investigator outside of the National Cancer Institute,” said Delcath President and CEO Richard L. Taney. “As the oncology community becomes more familiar with the potential benefits of Delcath’s PHP technology, this presentation will further the awareness of the Interventional Radiology Community, which will be a key driver in the adoption of this unique treatment for inoperable cancers.”
WAIS is a regional society of physicians from the western states and Canada dedicated to vascular and interventional radiology, and image-guided techniques for the diagnosis and treatment of cancer and other illnesses.
“Delcath’s novel drug delivery platform is capable of delivering anti-cancer drugs at very high doses to a specific organ or region of the body while preventing these high doses of drug from entering the patient’s bloodstream,” a company news release states.
Let us hear your thoughts below: